

Photobiomodulation as a Treatment Modality for COVID-19 Sequelae

By Peter Newsom, MD

Complete References

1. Rubin, R., As Their Numbers Grow, COVID-19 “Long Haulers” Stump Experts. *JAMA*, 2020. **324**(14): p. 1381-1383.
2. Geppert, C.M.A., The Brain in COVID-19: No One Is Okay. *Federal Practitioner*, 2020(Vol 37 No 9).
3. Townsend, L., et al., Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. *PLOS ONE*, 2020. **15**(11): p. e0240784.
4. Komaroff, A.L. and L. Bateman, Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? *Frontiers in Medicine*, 2021. **7**.
5. Perrin, R., et al., Into the looking glass: Post-viral syndrome post COVID-19. *Medical Hypotheses*, 2020. **144**: p. 110055.
6. Vink, M. and A. Vink-Niese, Could Cognitive Behavioural Therapy Be an Effective Treatment for Long COVID and Post COVID-19 Fatigue Syndrome? Lessons from the Qure Study for Q-Fever Fatigue Syndrome. *Healthcare*, 2020. **8**(4): p. 552.
7. Orsucci, D., et al., Neurological features of COVID-19 and their treatment: a review. *Drugs in Context*, 2020. **9**: p. 1-12.
8. Ahmadi Karvigh, S., et al., Ischemic Stroke in Patients with COVID-19 Disease: A Report of 10 Cases from Iran. *Cerebrovascular Diseases*, 2020: p. 1-6.
9. Merkler, A.E., et al., Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza. *JAMA Neurology*, 2020. **77**(11): p. 1366-1372.
10. Fu, B., Y. Chen, and P. Li, 2019 novel coronavirus disease with secondary ischemic stroke: two case reports. *BMC Neurology*, 2021. **21**(1): p. 4.
11. Taquet, M., et al., Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. *The Lancet Psychiatry*, 2021. **8**(2): p. 130-140.
12. Schmahmann, J. and D. Pandya, Fiber Pathways of the Brain. Vol. xviii. 2006.



13. Fox, M.D. and M.E. Raichle, Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. *Nature Reviews Neuroscience*, 2007. **8**(9): p. 700-711.
 14. Kocsis, B., G. Viana Di Prisco, and R. Vertes, Theta Synchronization in the Limbic System: The role of Gudden's tegmental nuclei. *The European journal of neuroscience*, 2001. **13**: p. 381-8.
 15. Defelipe, J., et al., Cortical white matter: beyond the pale remarks, main conclusions and discussion. *Frontiers in neuroanatomy*, 2010. **4**: p. 4-4.
 16. Byrne, B. and G. Brainard, Chapter 56 - Seasonal Affective Disorder, in *Therapy in Sleep Medicine*, T.J. Barkoukis, et al., Editors. 2012, W.B. Saunders: Philadelphia. p. 695-704.
 17. Hertrich, I., S. Dietrich, and H. Ackermann, The Margins of the Language Network in the Brain. *Frontiers in Communication*, 2020. **5**(93).
 18. Wandell, B.A., The neurobiological basis of seeing words. *Annals of the New York Academy of Sciences*, 2011. **1224**(1): p. 63-80.
 19. Rademacher, J., et al., Measuring in Vivo Myelination of Human White Matter Fiber Tracts with Magnetization Transfer MR. *NeuroImage*, 1999. **9**(4): p. 393-406.
 20. Rokem, A., et al., The visual white matter: The application of diffusion MRI and fiber tractography to vision science. *Journal of Vision*, 2017. **17**(2): p. 4.
 21. Fields, R.D., Neuroscience. Change in the brain's white matter. *Science (New York, N.Y.)*, 2010. **330**(6005): p. 768-769.
 22. Grotheer, M., et al., Separate lanes for adding and reading in the white matter highways of the human brain. *Nature Communications*, 2019. **10**(1).
 23. Aghagoli, G., et al., Neurological Involvement in COVID-19 and Potential Mechanisms: A Review. *Neurocritical Care*, 2020.
 24. Pajo, A.T., et al., Neuropathologic findings of patients with COVID-19: a systematic review. *Neurological Sciences*, 2021.
 25. Katal, S., S. Balakrishnan, and A. Gholamrezanezhad, Neuroimaging and neurologic findings in COVID-19 and other coronavirus infections: A systematic review in 116 patients. *Journal of neuroradiology = Journal de neuroradiologie*, 2021. **48**(1): p. 43-50.
 26. Lee, M.-H., et al., Microvascular Injury in the Brains of Patients with Covid-19. *New England Journal of Medicine*, 2021. **384**(5): p. 481-483.
 27. Kremer, S., et al., Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study. *Radiology*, 2020. **297**(2): p. E242-E251.
 28. Lu, Y., et al., Cerebral Micro-Structural Changes in COVID-19 Patients – An MRI-based 3-month Follow-up Study. *EClinicalMedicine*, 2020. **25**: p. 100484.
 29. Zombori, L., et al., Severe cortical damage associated with COVID-19 case report. *Seizure*, 2021. **84**: p. 66-68.
 30. Archer, M.I., The post-viral syndrome: a review. *The Journal of the Royal College of General Practitioners*, 1987. **37**(298): p. 212-214.
 31. Facts about chickenpox. *Paediatrics & Child Health*, 2005. **10**(7): p. 413-414.
 32. Burrell, C.J., C.R. Howard, and F.A. Murphy, *Pathogenesis of Virus Infections*. 2017, Elsevier. p. 77-104.
 33. Baron, S., M. Fons, and T. Albrecht, Viral Pathogenesis, in *Medical Microbiology*, S. Baron, Editor. 1996, University of Texas Medical Branch at Galveston
- Copyright © 1996, The University of Texas Medical Branch at Galveston.: Galveston (TX).

34. Ayala-Nunez, N.V. and R. Gaudin, A viral journey to the brain: Current considerations and future developments. *PLOS Pathogens*, 2020. **16**(5): p. e1008434.
35. Bauer, H.-C., et al., You Shall Not Pass tight junctions of the blood brain barrier. *Frontiers in Neuroscience*, 2014. **8**.
36. Sandoval, K.E. and K.A. Witt, Blood-brain barrier tight junction permeability and ischemic stroke. *Neurobiology of Disease*, 2008. **32**(2): p. 200-219.
37. Di Cristanziano, V., et al., Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia. *Bone Marrow Transplantation*, 2020.
38. Dando, S.J., et al., Pathogens Penetrating the Central Nervous System: Infection Pathways and the Cellular and Molecular Mechanisms of Invasion. *Clinical Microbiology Reviews*, 2014. **27**(4): p. 691-726.
39. Yarlagadda, A., E. Alfson, and A.H. Clayton, The blood brain barrier and the role of cytokines in neuropsychiatry. *Psychiatry* (Edgmont (Pa. : Township)), 2009. **6**(11): p. 18-22.
40. St-Amour, I., et al., Brain Bioavailability of Human Intravenous Immunoglobulin and its Transport through the Murine Blood–Brain Barrier. *Journal of Cerebral Blood Flow & Metabolism*, 2013. **33**(12): p. 1983-1992.
41. Semeraro, N. and M. Colucci, Endothelial Cell Perturbation and Disseminated Intravascular Coagulation. 2000.
42. Hasan, A.A.K., T. Zisman, and A.H. Schmaier, Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. *Proceedings of the National Academy of Sciences*, 1998. **95**(7): p. 3615-3620.
43. Newton, K. and V.M. Dixit, Signaling in Innate Immunity and Inflammation. *Cold Spring Harbor Perspectives in Biology*, 2012. **4**(3): p. a006049-a006049.
44. Popiolek-Barczyk, K. and J. Mika, Targeting the Microglial Signaling Pathways: New Insights in the Modulation of Neuropathic Pain. *Current Medicinal Chemistry*, 2016. **23**(26): p. 2908-2928.
45. Barnett, E.M., et al., Herpes Simplex Encephalitis in the Temporal Cortex and Limbic System after Trigeminal Nerve Inoculation. *Journal of Infectious Diseases*, 1994. **169**(4): p. 782-786.
46. Zhang, X., et al., Brain control of humoral immune responses amenable to behavioural modulation. *Nature*, 2020. **581**(7807): p. 204-208.
47. Rosas-Ballina, M., et al., Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. *Proceedings of the National Academy of Sciences*, 2008. **105**(31): p. 11008-11013.
48. Goldberg, M.F. and M.F. Goldberg, Neuroradiologic manifestations of COVID-19: what the emergency radiologist needs to know. *Emergency Radiology*, 2020. **27**(6): p. 737-745.
49. Meinhardt, J., et al., Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nature Neuroscience*, 2021. **24**(2): p. 168-175.
50. Edén, A., et al., CSF biomarkers in patients with COVID-19 and neurological symptoms. *Neurology*, 2020: p. 10.1212/WNL.000.
51. Cron, R.Q., COVID-19 cytokine storm: targeting the appropriate cytokine. *The Lancet Rheumatology*, 2021.

52. Najjar, S., et al., Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. *Journal of Neuroinflammation*, 2020. **17**(1).
53. Balcioglu, Y.H., et al., May the Central Nervous System Be Fogged by the Cytokine Storm in COVID-19?: an Appraisal. *Journal of Neuroimmune Pharmacology*, 2020. **15**(3): p. 343-344.
54. Yazdanpanah, F., M.R. Hamblin, and N. Rezaei, The immune system and COVID-19: Friend or foe? *Life sciences*, 2020. **256**: p. 117900-117900.
55. Li, N., et al., METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection. *Cell Rep*, 2021. **35**(6): p. 109091.
56. Fajnzylber, J., et al., SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nature Communications*, 2020. **11**(1): p. 5493.
57. Hojyo, S., et al., How COVID-19 induces cytokine storm with high mortality. *Inflamm Regen*, 2020. **40**: p. 37.
58. Alcock, J. and A. Masters, Cytokine storms, evolution and COVID-19. *Evolution, Medicine, and Public Health*, 2021. **9**(1): p. 83-92.
59. Østergaard, L., SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. *Physiol Rep*, 2021. **9**(3): p. e14726.
60. Huang, X., B. Hussain, and J. Chang, Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms. *CNS Neuroscience & Therapeutics*, 2021. **27**(1): p. 36-47.
61. da Silva Chagas, L., et al., Neuroinflammation and Brain Development: Possible Risk Factors in COVID-19-Infected Children. *Neuroimmunomodulation*, 2021. **28**(1): p. 22-28.
62. Chrousos, G.P. and G.U. Meduri, Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy. *Clinical immunology* (Orlando, Fla.), 2020. **219**: p. 108550-108550.
63. Arias, C., et al., Interference of SARS-CoV-2 with the Homeostasis of Ventilation and Perfusion in the Lung. 2020.
64. Tremblay, M.-E., et al., Neuropathobiology of COVID-19: The Role for Glia. *Frontiers in cellular neuroscience*, 2020. **14**: p. 592214-592214.
65. Gonçalves de Andrade, E., et al., Microglia Fighting for Neurological and Mental Health: On the Central Nervous System Frontline of COVID-19 Pandemic. *Frontiers in Cellular Neuroscience*, 2021. **15**(12).
66. Wagner, K.R., et al., Heme and iron metabolism: role in cerebral hemorrhage. *J Cereb Blood Flow Metab*, 2003. **23**(6): p. 629-52.
67. Martinez-Ramirez, S., S.M. Greenberg, and A. Viswanathan, Cerebral microbleeds: overview and implications in cognitive impairment. *Alzheimer's Research & Therapy*, 2014. **6**(3): p. 33.
68. Garton, T., et al., Brain iron overload following intracranial haemorrhage. *Stroke and vascular neurology*, 2016. **1**(4): p. 172-184.
69. Martines, R., et al., Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States. *Emerging Infectious Disease journal*, 2020. **26**(9): p. 2005.
70. Kruer, M.C., The neuropathology of neurodegeneration with brain iron accumulation. *International review of neurobiology*, 2013. **110**: p. 165-194.

71. Liu, J., Z. Kou, and Y. Tian, Diffuse axonal injury after traumatic cerebral microbleeds: an evaluation of imaging techniques. *Neural regeneration research*, 2014. **9**(12): p. 1222-1230.
72. Nuzzo, D. and P. Picone, Potential neurological effects of severe COVID-19 infection. *Neuroscience research*, 2020. **158**: p. 1-5.
73. Kann, O. and R. Kovács, Mitochondria and neuronal activity. *American Journal of Physiology-Cell Physiology*, 2007. **292**(2): p. C641-C657.
74. Rango, M. and N. Bresolin, Brain Mitochondria, Aging, and Parkinson's Disease. *Genes*, 2018. **9**(5): p. 250.
75. Misgeld, T. and T.L. Schwarz, Mitostasis in Neurons: Maintaining Mitochondria in an Extended Cellular Architecture. *Neuron*, 2017. **96**(3): p. 651-666.
76. Komaroff, A.L. and L. Bateman, Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? *Frontiers in Medicine*, 2021. **7**(1132).
77. Harkness, R.A. and O.D. Saugstad, The importance of the measurement of ATP depletion and subsequent cell damage with an estimate of size and nature of the market for a practicable method: a review designed for technology transfer. *Scand J Clin Lab Invest*, 1997. **57**(8): p. 655-72.
78. Graham, E.L., et al., Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". *Ann Clin Transl Neurol*, 2021. **8**(5): p. 1073-1085.
79. Hamblin, M.R. and Y.-Y. Huang, Photobiomodulation in the brain : low-level laser (light) therapy in neurology and neuroscience. 1. ed. 2019, Waltham: Elsevier. pages cm.
80. Hamblin, M.R., Shining light on the head: Photobiomodulation for brain disorders. *BBA clinical*, 2016. **6**: p. 113-124.
81. Yang, L., et al., Photobiomodulation therapy promotes neurogenesis by improving post-stroke local microenvironment and stimulating neuroprogenitor cells. *Experimental neurology*, 2018. **299**(Pt A): p. 86-96.
82. Hennessy, M. and M.R. Hamblin, Photobiomodulation and the brain: a new paradigm. *Journal of optics* (2010), 2017. **19**(1): p. 013003-013003.
83. Silva, G., et al., Infrared photobiomodulation (PBM) therapy improves glucose metabolism and intracellular insulin pathway in adipose tissue of high-fat fed mice. *Lasers Med Sci*, 2018. **33**(3): p. 559-571.
84. Hamblin, M.R., Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. *AIMS biophysics*, 2017. **4**(3): p. 337-361.
85. Eells, J.T., et al., 670 nm Photobiomodulation as a Therapy for Diabetic Macular Edema: A Pilot Study. *Investigative Ophthalmology & Visual Science*, 2017. **58**(8): p. 932-932.
86. Uozumi, Y., et al., Targeted increase in cerebral blood flow by transcranial near-infrared laser irradiation. *Lasers Surg Med*, 2010. **42**(6): p. 566-76.
87. Chang, S.Y., et al., Enhanced mitochondrial membrane potential and ATP synthesis by photobiomodulation increases viability of the auditory cell line after gentamicin-induced intrinsic apoptosis. *Sci Rep*, 2019. **9**(1): p. 19248.
88. Iaccarino, H.F., et al., Gamma frequency entrainment attenuates amyloid load and modifies microglia. *Nature*, 2016. **540**(7632): p. 230-235.
89. Singer, A., et al., Noninvasive 40-Hz light flicker to recruit microglia and reduce amyloid beta load. *Nature Protocols*, 2018. **13**: p. 1.

90. Terman, M., et al., Chronic fatigue syndrome and seasonal affective disorder: Comorbidity, diagnostic overlap, and implication for treatment. *The American journal of medicine*, 1998. **105**: p. 115S-124S.
91. Nejatifard, M., et al., Probable positive effects of the photobiomodulation as an adjunctive treatment in COVID-19: A systematic review. *Cytokine*, 2021. **137**: p. 155312.
92. Tedford, C.E., et al., Quantitative analysis of transcranial and intraparenchymal light penetration in human cadaver brain tissue. *Lasers in Surgery and Medicine*, 2015. **47**(4): p. 312-322.
93. Yeagle, P.L., Chapter 10 - Membrane Proteins, in *The Membranes of Cells* (Third Edition), P.L. Yeagle, Editor. 2016, Academic Press: Boston. p. 219-268.
94. Abhang, P.A., B.W. Gawali, and S.C. Mehrotra, Chapter 2 - Technological Basics of EEG Recording and Operation of Apparatus, in *Introduction to EEG- and Speech-Based Emotion Recognition*, P.A. Abhang, B.W. Gawali, and S.C. Mehrotra, Editors. 2016, Academic Press. p. 19-50.
95. Murty, D., et al., Gamma oscillations weaken with age in healthy elderly in human EEG. *NeuroImage*, 2020. **215**: p. 116826.
96. Singer, A.C., et al., Noninvasive 40-Hz light flicker to recruit microglia and reduce amyloid beta load. *Nature Protocols*, 2018. **13**(8): p. 1850-1868.
97. He, Q., et al., A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer's disease. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, 2021. **7**(1): p. e12178.
98. Glickman, G., et al., Light therapy for seasonal affective disorder with blue narrow-band light-emitting diodes (LEDs). *Biol Psychiatry*, 2006. **59**(6): p. 502-7.
99. Gordijn, M.C.M., D. t Mannetje, and Y. Meesters, The effects of blue-enriched light treatment compared to standard light treatment in seasonal affective disorder. *Journal of Affective Disorders*, 2012. **136**(1): p. 72-80.

MycoPul™ Exceptionally pure,
vigorous mycotoxin
binder



**Researched
Nutritionals**
solutions for life